CBNPC stade IV: Quel est le meilleur traitement de la rechute ?
作者： J.-P. Sculier
DOI: 10.1016/S0761-8425(06)72052-6
关键词:
摘要: Resume Le traitement medical de la rechute des cancers bronchiques non a petites cellules au stade avance est entre dans pratique medicale courante. L’article fait le point sur sujet en revoyant l’experience personnelle l’auteur, les recommandations clinique disponibles, revues systematiques publiees, essais randomises, etudes d’implementation et therapeutiques ciblees.
ulb.ac.be
sci-hub.se 参考文章(31)
Browman G, Levine M, Newman T, Cowan Dh, The Ontario Cancer Treatment Practice Guidelines Initiative. Oncology. ,vol. 10, pp. 19- 22 ,(1996)
Jean-Paul Sculier, Anne-Pascale Meert, Thierry Berghmans, Céline Mascaux, N Iannino, Le docétaxel comme traitement de rattrapage pour les cancers bronchiques non à petites cellules : étude d'implémentation Revue Médicale de Bruxelles. ,vol. 26, pp. 153- 158 ,(2005)
Klastersky J, Sculier Jp, Libert P, Rocmans P, Mommen P, Dalesio O, Dumont Jp, Ravez P, Becquart D, Vandermoten G, Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium). Cancer treatment reports. ,vol. 70, pp. 773- 775 ,(1986)
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
V Georgoulias, A Agelidou, K Syrigos, A Rapti, M Agelidou, J Nikolakopoulos, A Polyzos, A Athanasiadis, E Tselepatiotis, N Androulakis, K Kalbakis, G Samonis, D Mavroudis, Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. British Journal of Cancer. ,vol. 93, pp. 763- 769 ,(2005) , 10.1038/SJ.BJC.6602748
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
F M Wachters, H J M Groen, B Biesma, F M N H Schramel, P E Postmus, J A Stigt, E F Smit, A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment British Journal of Cancer. ,vol. 92, pp. 15- 20 ,(2005) , 10.1038/SJ.BJC.6602268
Kate Sumpter, Catherine Harper-Wynne, Cheng Yeoh, Sanjay Popat, Sue Ashley, Alison Norton, Mary O’Brien, Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible? Lung Cancer. ,vol. 43, pp. 369- 370 ,(2004) , 10.1016/J.LUNGCAN.2003.09.019
Giuseppe Giaccone, Jose Antonio Rodriguez, EGFR inhibitors: what have we learned from the treatment of lung cancer? Nature Clinical Practice Oncology. ,vol. 2, pp. 554- 561 ,(2005) , 10.1038/NCPONC0341
Fabrice Barlési, William Jacot, Philippe Astoul, Jean-Louis Pujol, Second-line treatment for advanced non-small cell lung cancer: A systematic review Lung Cancer. ,vol. 51, pp. 159- 172 ,(2006) , 10.1016/J.LUNGCAN.2005.08.017